Occupational toxicology of asbestos-related malignancies

References

• World Health Organization. Elimination of asbestos-related diseases. 2006; Geneva; WHO/SDE/OEH/06.03.
   Google Scholar
• Henderson DW, Rodelsperger K, Woitowitz HJ, Leigh J. After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997–2004. Pathology 2004; 36:517–550.
   PubMed Web of Science ®Google Scholar
• Mossman BT, Gee JB. Asbestos-related diseases. N Engl J Med 1989; 320:1721–1730.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Chahinian AP. Mesothelioma. London: Martin Dunitz; 2002.
   Google Scholar
• Roggli VL, Oury TD, Sporn TA. Pathology of Asbestos-Associated Disease. New York: Springer; 2004.
   Google Scholar
• Hessel PA, Gamble JF, McDonald JC. Asbestos, asbestosis, and lung cancer: a critical assessment of the epidemiological evidence. Thorax 2005; 60:433–436.
   PubMed Web of Science ®Google Scholar
• Becklake MR, Bagatin E, Neder JA. Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century. Int J Tuberc Lung Dis 2007; 11:356–369.
   PubMed Web of Science ®Google Scholar
• Kamp DW. Asbestos-induced lung diseases: an update. Transl Res 2009; 153:143–152.
   PubMed Web of Science ®Google Scholar
• Motley RL, Patrick CWJ, Kearse AM. Medicolegal aspects of asbestos-related diseases: a plaintiff's attorney's perspective. In: Roggli VL, Oury TD, Sporn TA, eds. Pathology of Asbestos-Associated Disease. New York: Springer; 2004:355–376.
   Google Scholar
• Parnell AH. Medicolegal aspects of asbestos-related disease: a defendant's attorney's perspective. In: Roggli VL, Oury TD, Sporn TA, eds. Pathology of Asbestos-Associated Disease. New York: Springer; 2004:377–401.
   Google Scholar
• Holmes E, Garshick E. The reproducibility of the self-report of occupational exposure to asbestos and dust. J Occup Med 1991; 33:134–138.
   PubMedGoogle Scholar
• Ahrens W, Jockel KH, Brochard P, Bolm-Audorff U, Grossgarten K, Iwatsubo Y, Orlowski E, Pohlabeln H, Berrino F. Retrospective assessment of asbestos exposure–I. Case-control analysis in a study of lung cancer: efficiency of job-specific questionnaires and job exposure matrices. Int J Epidemiol 1993; 22(Suppl 2):S83–S95.
   PubMedGoogle Scholar
• Orlowski E, Pohlabeln H, Berrino F, Ahrens W, Bolm-Audorff U, Grossgarten K, Iwatsubo Y, Jöckel KH, Brochard P. Retrospective assessment of asbestos exposure–II. At the job level: complementarity of job-specific questionnaire and job exposure matrices. Int J Epidemiol 1993; 22(Suppl 2):S96–S105.
   PubMedGoogle Scholar
• Burdorf A, Swuste P. An expert system for the evaluation of historical asbestos exposure as diagnostic criterion in asbestos-related diseases. Ann Occup Hyg 1999; 43:57–66.
   PubMed Web of Science ®Google Scholar
• Rice C, Heineman EF. An asbestos job exposure matrix to characterize fiber type, length, and relative exposure intensity. Appl Occup Environ Hyg 2003; 18:506–512.
   PubMedGoogle Scholar
• Nam JM, Rice C, Gail MH. Comparison of asbestos exposure assessments by next-of-kin respondents, by an occupational hygienist, and by a job-exposure matrix from the National Occupational Hazard Survey. Am J Ind Med 2005; 47:443–450.
   PubMed Web of Science ®Google Scholar
• Dement JM, Kuempel ED, Zumwalde RD, Smith RJ, Stayner LT, Loomis D. Development of a fibre size-specific job-exposure matrix for airborne asbestos fibres. Occup Environ Med 2008; 65:605–612.
   PubMed Web of Science ®Google Scholar
• Swuste P, Dahhan M, Burdorf A. Linking expert judgement and trends in occupational exposure into a job-exposure matrix for historical exposure to asbestos in the Netherlands. Ann Occup Hyg 2008; 52:397–403.
   PubMed Web of Science ®Google Scholar
• Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997; 23:311–316.
   PubMed Web of Science ®Google Scholar
• Hillerdal G. Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med 1999; 56:505–513.
   PubMed Web of Science ®Google Scholar
• Gibbs AR, Pooley FD. Analysis and interpretation of inorganic mineral particles in “lung” tissues. Thorax 1996; 51:327–334.
   PubMed Web of Science ®Google Scholar
• Lim HS, Kim JY, Sakai K, Hisanaga N. Pulmonary asbestos and non-asbestos fiber concentrations in autopsied inhabitants in Pohang, Korea. Ind Health 2004; 42:163–170.
   PubMed Web of Science ®Google Scholar
• Tossavainen A, Kovalevsky E, Vanhala E, Tuomi T. Pulmonary mineral fibers after occupational and environmental exposure to asbestos in the Russian chrysotile industry. Am J Ind Med 2000; 37:327–333.
   PubMed Web of Science ®Google Scholar
• Anttila S, Karjalainen A, Taikina-aho O, Kyyronen P, Vainio H. Lung cancer in the lower lobe is associated with pulmonary asbestos fiber count and fiber size. Environ Health Perspect 1993; 101:166–170.
   PubMed Web of Science ®Google Scholar
• Wagner JC, Newhouse ML, Corrin B, Rossiter CE, Griffiths DM. Correlation between fibre content of the lung and disease in east London asbestos factory workers. Br J Ind Med 1988; 45:305–308.
   PubMedGoogle Scholar
• Green FH, Harley R, Vallyathan V, Althouse R, Fick G, Dement J, Mitha R, Pooley F. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. Occup Environ Med 1997; 54:549–559.
   PubMed Web of Science ®Google Scholar
• Rödelsperger K, Mándi A, Tossavainen A, Brückel B, Barbisan P, Woitowitz HJ. Inorganic fibres in the lung tissue of Hungarian and German lung cancer patients. Int Arch Occup Environ Health 2001; 74:133–138.
   PubMed Web of Science ®Google Scholar
• Teschler H, Thompson AB, Dollenkamp R, Konietzko N, Costabel U. Relevance of asbestos bodies in sputum. Eur Respir J 1996; 9:680–686.
   PubMed Web of Science ®Google Scholar
• de Klerk NH, Musk AW, Williams V, Filion PR, Whitaker D, Shilkin KB. Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom Gorge, W. Australia. Am J Ind Med 1996; 30:579–587.
   PubMed Web of Science ®Google Scholar
• Churg A, Vedal S. Fiber burden and patterns of asbestos-related disease in workers with heavy mixed amosite and chrysotile exposure. Am J Respir Crit Care Med 1994; 150:663–669.
   PubMed Web of Science ®Google Scholar
• Berry G. Models for mesothelioma incidence following exposure to fibers in terms of timing and duration of exposure and the biopersistence of the fibers. Inhal Toxicol 1999; 11:111–130.
   PubMed Web of Science ®Google Scholar
• Finkelstein MM, Dufresne A. Inferences on the kinetics of asbestos deposition and clearance among chrysotile miners and millers. Am J Ind Med 1999; 35:401–412.
   PubMed Web of Science ®Google Scholar
• Dodson RF, Hammar SP, Poye LW. A technical comparison of evaluating asbestos concentration by phase-contrast microscopy (PCM), scanning electron microscopy (SEM), and analytical transmission electron microscopy (ATEM) as illustrated from data generated from a case report. Inhal Toxicol 2008; 20:723–732.
   PubMed Web of Science ®Google Scholar
• Gylseth B, Churg A, Davis JM, Johnson N, Morgan A, Mowe G, Rogers A, Roggli V. Analysis of asbestos fibers and asbestos bodies in tissue samples from human lung. An international interlaboratory trial. Scand J Work Environ Health 1985; 11:107–110.
   PubMed Web of Science ®Google Scholar
• Roggli VL, Sanders LL. Asbestos content of lung tissue and carcinoma of the lung: a clinicopathologic correlation and mineral fiber analysis of 234 cases. Ann Occup Hyg 2000; 44:109–117.
   PubMed Web of Science ®Google Scholar
• Sartorelli P, Scancarello G, Romeo R, Marcianò G, Rottoli P, Arcangeli G, Palmi S. Asbestos exposure assessment by mineralogical analysis of bronchoalveolar lavage fluid. J Occup Environ Med 2001; 43:872–881.
   PubMed Web of Science ®Google Scholar
• Sporn TA, Roggli VL. Asbestosis. In: Roggli VL, Oury TD, Sporn TA, eds. Pathology of Asbestos-Associated Disease. New York: Springer; 2004:71–103.
   Google Scholar
• Roggli VL, Sharma A. Analysis of tissue mineral fiber content. In: Roggli VL, Oury TD, Sporn TA, eds. Pathology of Asbestos-Associated Disease. New York: Springer; 2004:309–354.
   Google Scholar
• Weiss W. Asbestosis: a marker for the increased risk of lung cancer among workers exposed to asbestos. Chest 1999; 115:536–549.
   PubMed Web of Science ®Google Scholar
• Mollo F, Magnani C, Bo P, Burlo P, Cravello M. The attribution of lung cancers to asbestos exposure: a pathologic study of 924 unselected cases. Am J Clin Pathol 2002; 117:90–95.
   PubMed Web of Science ®Google Scholar
• Churg A. Asbestos-related disease in the workplace and the environment: controversial issues. Monogr Pathol 1993; 36:54–77.
   PubMedGoogle Scholar
• Everatt RP, Smolianskiene G, Tossavainen A, Cicenas S, Jankauskas R. Occupational asbestos exposure among respiratory cancer patients in Lithuania. Am J Ind Med 2007; 50:455–463.
   PubMed Web of Science ®Google Scholar
• Steele JP, Klabatsa A, Fennell DA, Palläska A, Sheaff MT, Evans MT, Shamash J, Rudd RM. Prognostic factors in mesothelioma. Lung Cancer 2005; 49(Suppl 1):S49–S52.
   PubMedGoogle Scholar
• Yau G, Lock M, Rodrigues G. Systematic review of baseline low-dose CT lung cancer screening. Lung Cancer 2007; 58:161–170.
   PubMed Web of Science ®Google Scholar
• Postmus PE. Screening for lung cancer, an ongoing debate. Ann Oncol 2008; 19(Suppl 7):25–27.
   Google Scholar
• The International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355:1763–1771.
   PubMed Web of Science ®Google Scholar
• Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. J Am Med Assoc 2007; 297:953–961.
   PubMed Web of Science ®Google Scholar
• Yankelevitz DF. Screening for a cancer: acting on social responsibility. Am J Roentgenol 2007; 188:1171–1172.
   PubMed Web of Science ®Google Scholar
• Lee CI, Forman HP. CT screening for lung cancer: implications on social responsibility. Am J Roentgenol 2007; 188:297–298.
   PubMed Web of Science ®Google Scholar
• Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000; 343:1627–1633.
   PubMed Web of Science ®Google Scholar
• Gohagan JK, Marcus PM, Fagerstrom RM, Pinsky PF, Kramer BS, Prorok PC, Ascher S, Bailey W, Brewer B, Church T, Engelhard D, Ford M, Fouad M, Freedman M, Gelmann E, Gierada D, Hocking W, Inampudi S, Irons B, Johnson CC, Jones A, Kucera G, Kvale P, Lappe K, Manor W, Moore A, Nath H, Neff S, Oken M, Plunkett M, Price H, Reding D, Riley T, Schwartz M, Spizarny D, Yoffie R, Zylak C, Lung Screening Study Research Group. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 2005; 47:9–15.
   PubMed Web of Science ®Google Scholar
• Mollo F, Pira E, Piolatto G, Bellis D, Burlo P, Andreozzi A, Bontempi S, Negri E. Lung adenocarcinoma and indicators of asbestos exposure. Int J Cancer 1995; 60:289–293.
   PubMed Web of Science ®Google Scholar
• Tiitola M, Kivisaari L, Huuskonen MS, Mattson K, Koskinen H, Lehtola H, Zitting A, Vehmas T. Computed tomography screening for lung cancer in asbestos-exposed workers. Lung Cancer 2002; 35:17–22.
   PubMed Web of Science ®Google Scholar
• Das M, Mühlenbruch G, Mahnken AH, Hering KG, Sirbu H, Zschiesche W, Knoll L, Felten MK, Kraus T, Günther RW, Wildberger JE. Asbestos Surveillance Program Aachen (ASPA): initial results from baseline screening for lung cancer in asbestos-exposed high-risk individuals using low-dose multidetector-row CT. Eur Radiol 2007; 17:1193–1199.
   PubMed Web of Science ®Google Scholar
• Fasola G, Belvedere O, Aita M, Zanin T, Follador A, Cassetti P, Meduri S, De Pangher V, Pignata G, Rosolen V, Barbone F, Grossi F. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial – an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist 2007; 12:1215–1224.
   PubMed Web of Science ®Google Scholar
• Vierikko T, Järvenpää R, Autti T, Oksa P, Huuskonen M, Kaleva S, Laurikka J, Kajander S, Paakkola K, Saarelainen S, Salomaa ER, Tossavainen A, Tukiainen P, Uitti J, Vehmas T. Chest CT screening of asbestos-exposed workers: lung lesions and incidental findings. Eur Respir J 2007; 29:78–84.
   PubMed Web of Science ®Google Scholar
• Mastrangelo G, Ballarin MN, Bellini E, Bizzotto R, Zannol F, Gioffrè F, Gobbi M, Tessadri G, Marchiori L, Marangi G, Bozzolan S, Lange JH, Valentini F, Spolaore P. Feasibility of a screening programme for lung cancer in former asbestos workers. Occup Med (Lond) 2008; 58:175–180.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367–1380.
   PubMed Web of Science ®Google Scholar
• Dalton WS, Friend SH. Cancer biomarkers – an invitation to the table. Science 2006; 312:1165–1168.
   PubMed Web of Science ®Google Scholar
• Hardy J, Singleton A. Genomewide association studies and human disease. N Engl J Med 2009; 360:1759–1768.
   PubMed Web of Science ®Google Scholar
• Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008; 40:616–622.
   PubMed Web of Science ®Google Scholar
• Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chen C, Goodman G, Field JK, Liloglou T, Xinarianos G, Cassidy A, McLaughlin J, Liu G, Narod S, Krokan HE, Skorpen F, Elvestad MB, Hveem K, Vatten L, Linseisen J, Clavel-Chapelon F, Vineis P, Bueno-de-Mesquita HB, Lund E, Martinez C, Bingham S, Rasmuson T, Hainaut P, Riboli E, Ahrens W, Benhamou S, Lagiou P, Trichopoulos D, Holcátová I, Merletti F, Kjaerheim K, Agudo A, Macfarlane G, Talamini R, Simonato L, Lowry R, Conway DI, Znaor A, Healy C, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452:633–637.
   PubMed Web of Science ®Google Scholar
• Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 2008; 14:2878–2886.
   PubMed Web of Science ®Google Scholar
• Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN, Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T, Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ, Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ, Gudbjartsson T, Jones GT, Mueller T, Gottsäter A, Flex A, Aben KK, de Vegt F, Mulders PF, Isla D, Vidal MJ, Asin L, Saez B, Murillo L, Blondal T, Kolbeinsson H, Stefansson JG, Hansdottir I, Runarsdottir V, Pola R, Lindblad B, van Rij AM, Dieplinger B, Haltmayer M, Mayordomo JI, Kiemeney LA, Matthiasson SE, Oskarsson H, Tyrfingsson T, Gudbjartsson DF, Gulcher JR, Jonsson S, Thorsteinsdottir U, Kong A, Stefansson K. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452:638–642.
   PubMed Web of Science ®Google Scholar
• Ma PC, Blaszkowsky L, Bharti A, Ladanyi A, Kraeft SK, Bruno A, Skarin AT, Chen LB, Salgia R. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res 2003; 23:49–62.
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Spanevello A, Curci C, Salerno F, Palladino GP, Resta O, Di Gioia G, Carpagnano F, Foschino Barbaro MP. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients. Oncol Res 2007; 16:375–381.
   PubMed Web of Science ®Google Scholar
• Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004; 22:4157–4164.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 1996; 2:1033–1035.
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, Haney J, Kennedy TC, Hirsch FR, Miller Y, Franklin WA, Herman JG, Baylin SB, Bunn PA, Byers T. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006; 66:3338–3344.
   PubMed Web of Science ®Google Scholar
• Belinsky SA, Grimes MJ, Casas E, Stidley CA, Franklin WA, Bocklage TJ, Johnson DH, Schiller JH. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007; 96:1278–1283.
   PubMed Web of Science ®Google Scholar
• Patz EF, Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE, 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007; 25:5578–5583.
   PubMed Web of Science ®Google Scholar
• Bharti A, Ma PC, Salgia R. Biomarker discovery in lung cancer–promises and challenges of clinical proteomics. Mass Spectrom Rev 2007; 26:451–466.
   PubMed Web of Science ®Google Scholar
• Baker SG, Kramer BS, McIntosh M, Patterson BH, Shyr Y, Skates S. Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials 2006; 3:43–56.
   PubMed Web of Science ®Google Scholar
• Nymark P, Wikman H, Ruosaari S, Hollmen J, Vanhala E, Karjalainen A, Anttila S, Knuutila S. Identification of specific gene copy number changes in asbestos-related lung cancer. Cancer Res 2006; 66:5737–5743.
   PubMed Web of Science ®Google Scholar
• Wikman H, Ruosaari S, Nymark P, Sarhadi VK, Saharinen J, Vanhala E, Karjalainen A, Hollmén J, Knuutila S, Anttila S. Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer. Oncogene 2007; 26:4730–4737.
   PubMed Web of Science ®Google Scholar
• Andujar P, Wang J, Descatha A, Galateau-Salle F, Abd-Alsamad I, Billon-Galland MA, Blons H, Clin B, Danel C, Housset B, Laurent-Puig P, Le Pimpec-Barthes F, Letourneux M, Monnet I, Régnard JF, Renier A, Zucman-Rossi J, Pairon JC, Jaurand MC. p16(INK4A) inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer 2010; 67:23–30.
   PubMed Web of Science ®Google Scholar
• Björkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 1997; 75:523–527.
   PubMed Web of Science ®Google Scholar
• Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. Cancer Genet Cytogenet 2001; 127:93–110.
   PubMed Web of Science ®Google Scholar
• Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer 2005; 49(Suppl 1):S95–S98.
   PubMed Web of Science ®Google Scholar
• Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61:5959–5963.
   PubMed Web of Science ®Google Scholar
• Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002; 23:1127–1130.
   PubMed Web of Science ®Google Scholar
• Bianchi AB, Mitsunaga SI, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, Kley N, Klein-Szanto AJ, Testa JR. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995; 92:10854–10858.
   PubMed Web of Science ®Google Scholar
• Baser ME. Contributors to the International NF2 Mutation Database. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 2006; 27:297–306.
   PubMed Web of Science ®Google Scholar
• Sekido Y. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Cancer Sci 2010; 101:1–6.
   PubMed Web of Science ®Google Scholar
• Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353:1564–1573.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362:1612–1616.
   PubMed Web of Science ®Google Scholar
• Cullen MR. Serum osteopontin levels – is it time to screen asbestos-exposed workers for pleural mesothelioma? N Engl J Med 2005; 353:1617–1618.
   PubMed Web of Science ®Google Scholar
• Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 2007; 62:569–576.
   PubMed Web of Science ®Google Scholar
• Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol 2007; 20:215–220.
   PubMed Web of Science ®Google Scholar
• Minna JD. Neoplasms of the lung. In: Kasper DL, Braunwald E, Fauci A, Hauser SL, Longo DL, Jamesson JL, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill Medical Publishing Division; 2005:506–516.
   Google Scholar
• Alberg AJ, Ford JG, Samet JM, American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132(Suppl 3):S29–S55.
   PubMed Web of Science ®Google Scholar
• Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001; 31:139–148.
   PubMed Web of Science ®Google Scholar
• Dubey S, Powell CA. Update in lung cancer 2007. Am J Respir Crit Care Med 2008; 177:941–946.
   PubMed Web of Science ®Google Scholar
• Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers–a different disease. Nat Rev Cancer 2007; 7:778–790.
   PubMed Web of Science ®Google Scholar
• Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008; 9:676–682.
   PubMed Web of Science ®Google Scholar
• Lash TL, Crouch EA, Green LC. A meta-analysis of the relation between cumulative exposure to asbestos and relative risk of lung cancer. Occup Environ Med 1997; 54:254–263.
   PubMed Web of Science ®Google Scholar
• Hodgson JT, Darnton A. The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg 2000; 44:565–601.
   PubMed Web of Science ®Google Scholar
• Berry G, Gibbs GW. An overview of the risk of lung cancer in relation to exposure to asbestos and of taconite miners. Regul Toxicol Pharmacol 2008; 52(Suppl 1):S218–S222.
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66:1191–1308.
   PubMed Web of Science ®Google Scholar
• Gustavsson P, Ahlbom A, Andersson T, Schéele P. Calculation of fractions of lung cancer incidence attributable to occupational exposure to asbestos and combustion products in Stockholm, Sweden. Eur J Epidemiol 2003; 18:937–940.
   PubMed Web of Science ®Google Scholar
• Marinaccio A, Scarselli A, Binazzi A, Mastrantonio M, Ferrante P, Iavicoli S. Magnitude of asbestos-related lung cancer mortality in Italy. Br J Cancer 2008; 99:173–175.
   PubMed Web of Science ®Google Scholar
• Craighead JE, Mossman BT. The pathogenesis of asbestos-associated diseases. N Engl J Med 1982; 306:1446–1455.
   PubMed Web of Science ®Google Scholar
• Lee BW, Wain JC, Kelsey KT, Wiencke JK, Christiani DC. Association of cigarette smoking and asbestos exposure with location and histology of lung cancer. Am J Respir Crit Care Med 1998; 157:748–755.
   PubMed Web of Science ®Google Scholar
• Boffetta P. Health effects of asbestos exposure in humans: a quantitative assessment. Med Lav 1998; 89:471–480.
   PubMedGoogle Scholar
• McDonald J. Asbestos related disease: an epidemiological review. In: Wagner JC, ed. Biological Effects of Mineral Fibers. Lyon: International Agency for Research on Cancer; 1980:811–817 (Scientific publication no. 30).
   Google Scholar
• McDonald AD, Fry JS, Woolley AJ, McDonald JC. Dust exposure and mortality in an American chrysotile asbestos friction products plant. Br J Ind Med 1984; 41:151–157.
   PubMedGoogle Scholar
• Finkelstein MM. Mortality among long-term employees of an Ontario asbestos-cement factory. Br J Ind Med 1983; 40:138–144.
   PubMedGoogle Scholar
• Weill H, Hughes J, Waggenspack C. Influence of dose and fiber type on respiratory malignancy risk in asbestos cement manufacturing. Am Rev Respir Dis 1979; 120:345–354.
   PubMed Web of Science ®Google Scholar
• McDonald AD, Fry JS, Woolley AJ, McDonald J. Dust exposure and mortality in an American chrysotile textile plant. Br J Ind Med 1983; 40:361–367.
   PubMedGoogle Scholar
• McDonald AD, Fry JS, Woolley AJ, McDonald JC. Dust exposure and mortality in an American factory using chrysotile, amosite, and crocidolite in mainly textile manufacture. Br J Ind Med 1982; 39:368–374.
   Google Scholar
• Tossavainen A. International expert meeting on new advances in the radiology and screening of asbestos-related diseases. Scand J Work Environ Health 2000; 26:449–454.
   PubMedGoogle Scholar
• Pierce JS, McKinley MA, Paustenbach DJ, Finley BL. An evaluation of reported no-effect chrysotile asbestos exposures for lung cancer and mesothelioma. Crit Rev Toxicol 2008; 38:191–214.
   PubMed Web of Science ®Google Scholar
• Gibbs A, Attanoos RL, Churg A, Weill H. The “Helsinki criteria” for attribution of lung cancer to asbestos exposure: how robust are the criteria? Arch Pathol Lab Med 2007; 131:181–184.
   PubMed Web of Science ®Google Scholar
• Greenberg M. The “Helsinki Criteria” for attribution of lung cancer to asbestos exposure: how robust are the criteria? Arch Pathol Lab Med 2007; 131:1630.
   PubMed Web of Science ®Google Scholar
• Roggli VL, Hammar SP, Maddox JC, Henderson DW. Re: The “Helsinki Criteria” for attribution of lung cancer to asbestos exposure: how robust are the criteria? Arch Pathol Lab Med 2008; 132:1386–1387.
   PubMed Web of Science ®Google Scholar
• Camus M, Siemiatycki J, Meek B. Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer. N Engl J Med 1998; 338:1565–1571.
   PubMed Web of Science ®Google Scholar
• Egilman D, Reinert A. Lung cancer and asbestos exposure: asbestosis is not necessary. Am J Ind Med 1996; 30:398–406.
   PubMed Web of Science ®Google Scholar
• Reid A, de Klerk N, Ambrosini GL, Olsen N, Pang SC, Berry G, Musk AW. The effect of asbestosis on lung cancer risk beyond the dose related effect of asbestos alone. Occup Environ Med 2005; 62:885–889.
   PubMed Web of Science ®Google Scholar
• Hughes JM, Weill H. Asbestosis as a precursor of asbestos related lung cancer: results of a prospective mortality study. Br J Ind Med 1991; 48:229–233.
   PubMedGoogle Scholar
• Jones RN, Hughes JM, Weill H. Asbestos exposure, asbestosis, and asbestos-attributable lung cancer. Thorax 1996; 51(Suppl 2):S9–S15.
   PubMedGoogle Scholar
• Loomis D, Dement JM, Wolf SH, Richardson DB. Lung cancer mortality and fiber exposures among North Carolina asbestos textile workers. Occup Environ Med 2009; 66:535–542.
   PubMed Web of Science ®Google Scholar
• Oksa P, Klockars M, Karjalainen A, Huuskonen MS, Vattulainen K, Pukkala E, Nordman H. Progression of asbestosis predicts lung cancer. Chest 1998; 113:1517–1521.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170:691–715.
   PubMed Web of Science ®Google Scholar
• Adesina AM, Vallyathan V, McQuillen EN, Weaver SO, Craighead JE. Bronchiolar inflammation and fibrosis associated with smoking. A morphologic cross-sectional population analysis. Am Rev Respir Dis 1991; 143:144–149.
   PubMed Web of Science ®Google Scholar
• Ross RM. The clinical diagnosis of asbestosis in this century requires more than a chest radiograph. Chest 2003; 124:1120–1128.
   PubMed Web of Science ®Google Scholar
• Gamsu G, Salmon CJ, Warnock ML, Blanc PD. CT quantification of interstitial fibrosis in patients with asbestosis: a comparison of two methods. Am J Roentgenol 1995; 164:63–68.
   PubMed Web of Science ®Google Scholar
• Copley SJ, Wells AU, Sivakumaran P, Rubens MB, Lee YC, Desai SR, MacDonald SL, Thompson RI, Colby TV, Nicholson AG, du Bois RM, Musk AW, Hansell DM. Asbestosis and idiopathic pulmonary fibrosis: comparison of thin-section CT features. Radiology 2003; 229:731–736.
   PubMed Web of Science ®Google Scholar
• McDonald JC, Sebastien P, Armstrong B. Radiological survey of past and present vermiculite miners exposed to tremolite. Br J Ind Med 1986; 43:445–449.
   PubMedGoogle Scholar
• Van Cleemput J, De Raeve H, Verschakelen JA, Rombouts J, Lacquet LM, Nemery B. Surface of localized pleural plaques quantitated by computed tomography scanning: no relation with cumulative asbestos exposure and no effect on lung function. Am J Respir Crit Care Med 2001; 163:705–710.
   PubMed Web of Science ®Google Scholar
• Hillerdal G, Henderson DW. Asbestos, asbestosis, pleural plaques and lung cancer. Scand J Work Environ Health 1997; 23:93–103.
   PubMed Web of Science ®Google Scholar
• Weill D, Weill H. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2005; 171:527–528.
   PubMed Web of Science ®Google Scholar
• Wraith D, Mengersen K. A Bayesian approach to assess interaction between known risk factors: the risk of lung cancer from exposure to asbestos and smoking. Stat Methods Med Res 2008; 17:171–189.
   PubMed Web of Science ®Google Scholar
• Nelson HH, Kelsey KT. The molecular epidemiology of asbestos and tobacco in lung cancer. Oncogene 2002; 21:7284–7288.
   PubMed Web of Science ®Google Scholar
• Churg A, Stevens B. Enhanced retention of asbestos fibers in the airways of human smokers. Am J Respir Crit Care Med 1995; 151:1409–1413.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Harris CC, Muller-Hermelink HK. World Health Organization Classification of Tumors. Pathology and Genetics: Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC, 2004:128–136.
   Google Scholar
• Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004; 14:447–460.
   PubMedGoogle Scholar
• Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: an update. Arch Pathol Lab Med 2005; 129:1407–1414.
   PubMed Web of Science ®Google Scholar
• Galateau-Salle F, Brambilla E, Cagle P. Pathology of Malignant Mesothelioma. International Mesothelioma Panel. London: Springer-Verlag; 2006.
   Google Scholar
• Attanoos RL, Dojcinov SD, Webb R, Gibbs AR. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Histopathology 2000; 37:224–231.
   PubMed Web of Science ®Google Scholar
• Doglioni C, Dei Tos AP, Laurino L, Iuzzolino P, Chiarelli C, Celio MR, Viale G. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996; 20:1037–1046.
   PubMed Web of Science ®Google Scholar
• Suster S, Moran CA. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol 2006; 13:316–329.
   PubMed Web of Science ®Google Scholar
• Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998; 11:929–933.
   PubMed Web of Science ®Google Scholar
• Granville LA, Younes M, Churg A, Roggli VL, Henderson DW, Cagle PT. Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol 2005; 13:75–79.
   PubMedGoogle Scholar
• Churg A, Colby TV, Cagle P, Corson J, Gibbs AR, Gilks B, Grimes M, Hammar S, Roggli V, Travis WD. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24:1183–1200.
   PubMed Web of Science ®Google Scholar
• Cagle PT, Churg A. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies. Arch Pathol Lab Med 2005; 129:1421–1427.
   PubMed Web of Science ®Google Scholar
• Kerrigan SA, Cagle P, Churg A. Malignant mesothelioma of the peritoneum presenting as an inflammatory lesion: a report of four cases. Am J Surg Pathol 2003; 27:248–253.
   PubMed Web of Science ®Google Scholar
• Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 1998; 110:397–404.
   PubMed Web of Science ®Google Scholar
• Triol JH, Conston AS, Chandler SV. Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey community hospital. Acta Cytol 1984; 28:37–45.
   PubMed Web of Science ®Google Scholar
• Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997; 111:106–109.
   PubMed Web of Science ®Google Scholar
• el-Habashi A, el-Morsi B, Freeman SM, el-Didi M, Marrogi AJ. Tumor oncogenic expression in malignant effusions as a possible method to enhance cytologic diagnostic sensitivity. An immunocytochemical study of 87 cases. Am J Clin Pathol 1995; 103:206–214.
   PubMed Web of Science ®Google Scholar
• Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol 1992; 9:124–140.
   PubMed Web of Science ®Google Scholar
• Ko EC, Jhala NC, Shultz JJ, Chhieng DC. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Am J Clin Pathol 2001; 116:709–715.
   PubMed Web of Science ®Google Scholar
• Attanoos RL, Gibbs AR. An approach to industrial post mortems. Histopathology 2009; 54:134–142.
   PubMed Web of Science ®Google Scholar
• Cagle PT. Criteria for attributing lung cancer to asbestos exposure. Am J Clin Pathol 2002; 117:9–15.
   PubMed Web of Science ®Google Scholar
• Case BW. Asbestos, smoking, and lung cancer: interaction and attribution. Occup Environ Med 2006; 63:507–508.
   PubMed Web of Science ®Google Scholar
• Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 2002; 29:41–50.
   PubMed Web of Science ®Google Scholar
• King JE, Hasleton PS. Immunohistochemistry and the diagnosis of malignant mesothelioma. Histopathology 2001; 38:471–476.
   PubMed Web of Science ®Google Scholar
• Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, Baronchelli C, Lucini L, Santin A, Murer B. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 2007; 451:669–680.
   PubMed Web of Science ®Google Scholar
• Banks DE, Shi R, McLarty J, Cowl CT, Smith D, Tarlo SM, Daroowalla F, Balmes J, Baumann M. American College of Chest Physicians consensus statement on the respiratory health effects of asbestos. Results of a Delphi study. Chest 2009; 135:1619–1627.
   PubMed Web of Science ®Google Scholar